Fernandez-Rodriguez CM,Gutierrez-Garcia ML.Prevention of hepatocellular carcinoma in patients with chronic hepatitis B[J].World J Gastrointest Pharmacol Ther,2014,5(3):175-182.
[3]
Liaw YF.Impact of therapy on the outcome of chronic hepatitis B[J].Liver Int,2013,33(Suppl 1):111-115.
[4]
Komatsu S,Ichikawa D,Takeshita H,et al.Circulating miR-18a:a sensitive cancer screening biomarker in human cancer[J].In Vivo,2014,28(3):293-297.
[5]
Tan W,Li Y,Lim SG,et al.miR-106b-25/miR-17-92clusters:polycistrons with oncogenic roles in hepatocellular carcinoma[J].World J Gastroenterol,2014,20(20):5 962-5 972.
[6]
Giray BG,Emekdas G,Tezcan S,et al.Profiles of serum microRNAs;miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma[J].Mol Biol Rep,2014,41(7):4 513-4 519.
[7]
Behne T,Copur MS.Biomarkers for hepatocellular carcinoma[J].Int J Hepatol,2012,2012:859 076.
[8]
Melo SA,Esteller M.Dysregulation of microRNAs in cancer:playing with fire[J].FEBS Lett,2011,585(13):2 087-2 099.
[9]
Lawrie CH,Gal S,Dunlop HM,et al.Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma[J].Br J Haematol,2008,141(5):672-675.
[10]
Xu J,Wu C,Che X,et al.Circulating microRNAs,miR-21,miR-122,and miR-223,in patients with hepatocellular carcinoma or chronic hepatitis[J].Mol Carcinog,2011,50(2):136-142.
[11]
Qi P,Cheng SQ,Wang H,et al.Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection[J].PLoS One,2011,6(12):e28486.
[12]
Zhou J,Yu L,Gao X,et al.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J].J Clin Oncol,2011,29(36):4 781-4 788.
[13]
Tan Y,Ge G,Pan T,et al.A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus[J].PLoS One,2014,9(9):e107 986.
[14]
Meng FL,Wang W,Jia WD.Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma[J].Med Oncol,2014,31(9):177.
[15]
El-Serag HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J].Gastroenterology,2012,142(6):1 264-1 273.
[16]
Wei X,Xiang T,Ren G,et al.miR-101is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A[J].Cell Signal,2013,25(2):439-446.
[17]
Sheng Y,Li J,Zou C,et al.Downregulation of miR-101-3p by hepatitis B virus promotes proliferation and migration of hepatocellular carcinoma cells by targeting Rab5a[J].Arch Virol,2014,159(9):2 397-2 410.
[18]
Tarocchi M,Polvani S,Marroncini G,et al.Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis[J].World J Gastroenterol,2014,20(33):11 630-11 640.
[19]
Schiff ER,Lee SS,Chao YC,et al.Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B[J].Clin Gastroenterol Hepatol,2011,9(3):274-276.
[20]
Marcellin P,Gane E,Buti M,et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label followup study[J].Lancet,2013,381(9 865):468-475.
Jelic S,Sotiropoulos GC.Hepatocellular carcinoma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2010,21(Suppl5):v59-v64.
[23]
Wang L,Yao M,Dong Z,et al.Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring[J].Tumour Biol,2014,35(1):9-20.
[24]
Abdalla MA,Haj-Ahmad Y.Promising urinary protein biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus egyptian patients[J].J Cancer,2012,3:390-403.
[25]
Choi J,Park Y,Kim JH,et al.Evaluation of automated serum des-gamma-carboxyprothrombin(DCP)assays for detecting hepatocellular carcinoma[J].Clin Biochem,2011,44:1 464-1 468.
[26]
Tseng TC,Liu CJ,Yang HC,et al.High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load[J].Gastroenterology,2012,142(5):1 140-1 149,e13-e14.
Zhang LY,Liu M,Li X,et al.miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3(ERGIC3)[J].J Biol Chem,2013,288(6):4 035-4 047.
[29]
Li L,Guo Z,Wang J,et al.Serum miR-18a:apotential marker for hepatitis B virus-related hepatocellular carcinoma screening[J].Dig Dis Sci,2012,57(11):2 910-2 916.
[30]
Zhang Z,Chen J,He Y,et al.miR-125binhibits hepatitis B virus expression in vitro through targeting of the SCNN1A gene[J].Arch Virol,2014,159(12):3 335-3 343.
